Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium:Estrogen receptor mutations in patients With HR-positive/HER2-negative advanced breast cancerCurrent guideline recommendations for when to pursue ESR1 mutation testing mutations in patients with HR-positive/HER2-negative advanced breast cancerChoice and sequencing of next line of systemic therapy for ESR1-mutated advanced breast cancer based on tumor molecular alterationsOverview of class-related and unique adverse events with approved and emerging oral SERDSExpert recommendations for the management of oral SERDs-related adverse eventsProgram faculty:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasErica L. Mayer, MD, MPHDirector of Breast Cancer Clinical ResearchDana-Farber Cancer InstituteAssociate Professor in MedicineHarvard Medical SchoolBoston, MassachusettsLaura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Resources:To download the slides associated with this podcast discussion, please visit the program page.

There are no comments yet.

Please log in to write the first comment.